BB106 (Ketamine)

About Bexson Biomedical

Bexson Biomedical is a pre-revenue, private biotech developing a novel drug delivery platform centered on its patented SeVALENT™ technology, a 7-valence salt system that enhances the solubility and subcutaneous delivery of small molecules. The company is leveraging this platform to repurpose existing drugs, such as ketamine and flumazenil, for at-home use via a wearable pump, while also exploring new chemical entities. With a focus on pain, addiction, and mental health, Bexson aims to de-risk development, extend patent lifecycles, and improve health economics through remote care.

Therapeutic Areas